Evidence map›Paper›PMID 32857676›Full record

ArticleTissue barriers2020

HMGB1 enhances epithelial permeability via p63/TGF-β signaling in lung and terminal bronchial epithelial cells.

Yuki Kodera, Takayuki Kohno, Takumi Konno, Wataru Arai, Mitsuhiro Tsujiwaki, Yuma Shindo, Hirofumi Chiba, Maki Miyakawa, Hiroki Tanaka, Yuji Sakuma and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Tissue barriers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Claudin-4: A New Molecular Target for Epithelial Cancer Therapy.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yuki KoderaDepartment of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine , Sapporo, Japan.
Takayuki KohnoDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine , Sapporo, Japan.
Takumi KonnoDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine , Sapporo, Japan.
Wataru AraiDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine , Sapporo, Japan.
Mitsuhiro TsujiwakiDepartment of Pathology, Sapporo Medical University School of Medicine , Sapporo, Japan.
Yuma ShindoDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine , Sapporo, Japan.
Hirofumi ChibaDepartment of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine , Sapporo, Japan.
Maki MiyakawaDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine , Sapporo, Japan.
Hiroki TanakaIBD Center, Sapporo Kosei General Hospital , Sapporo, Japan.
Yuji SakumaDepartment of Molecular Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine , Sapporo, Japan.
Atsushi WatanabeDepartment of Thoracic Surgery, Sapporo Medical University School of Medicine , Sapporo, Japan.
Hiroki TakahashiDepartment of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine , Sapporo, Japan.
Takashi KojimaDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine , Sapporo, Japan.
Sapporo Medical University · JPSapporo Kosei General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High mobility group box 1 (HMGB1) is involved in the induction of airway inflammation and injury in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). HMGB1 increased by transforming growth factor-β1 (TGF-β1), impairs airway epithelial barrier function in the lung. In the present study, to investigate how HMGB1 affects the barrier of normal human lung epithelial (HLE) cells, monolayer cells (2D culture) and bronchial-like spheroid cells (2.5 D Matrigel culture), which have lumen formation, were pretreated with TGF-β type I receptor kinase inhibitor EW-7197 before treatment with HMGB1. In 2D culture, treatment with HMGB1 decreased expression of angulin-1/LSR, TRIC and CLDN-1, -4, -7 and increased that of CLDN-2. Pretreatment with EW-7197 prevented the changes of all tight junction molecules induced by HMGB1. In 2.5D Matrigel culture, treatment with HMGB1 induced permeability of FITC-dextran (FD-4) into the lumen, whereas pretreatment with EW-7197 prevented the hyperpermeability of FD-4 into the lumen caused by HMGB1. In 2.5D Matrigel culture, knockdown of transcription factor p63 prevented the hyperpermeability induced by HMGB1 as well as pretreatment with EW-7197. In the 2D culture of HLE cells with HMGB1, knockdown of p63 increased the level of angulin-1/LSR and CLDN-4, while pretreatment with EW-7197 enhanced the increase of CLDN-4 induced by knockdown of p63. Immunohistochemical analysis of IPF, CLDN-2, HMGB1 and p63 revealed that their levels were higher in the regenerative epithelium of the terminal bronchial region than in normal epithelium. HMGB1 induces epithelial permeability of HLE cells via p63/TGF-β signaling in normal lung and IPF.

Indexed as

BronchiolesEpithelial CellsEpitheliumHMGB1 ProteinHumansMembrane ProteinsSignal TransductionTransforming Growth Factor beta1CKAP4 protein, humanHMGB1 ProteinMembrane ProteinsTGFB1 protein, humanTransforming Growth Factor beta12.5D Matrigel culturesepithelial permeabilityEW-7197HMGB1normal human lung epithelial cellsp63TGF-Βtight junctionsTNFα-antibody

Identifiers

PMID32857676
PMCPMC7714505
OpenAlexW3082397370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.